These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

352 related items for PubMed ID: 15686768

  • 1. Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein.
    Koenig W.
    Int J Cardiol; 2005 Feb 15; 98(2):199-206. PubMed ID: 15686768
    [Abstract] [Full Text] [Related]

  • 2. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S, Ridker PM.
    Am J Cardiol; 2006 Jan 16; 97(2A):33A-41A. PubMed ID: 16442935
    [Abstract] [Full Text] [Related]

  • 3. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus.
    Ridker PM.
    J Am Coll Cardiol; 2007 May 29; 49(21):2129-38. PubMed ID: 17531663
    [Abstract] [Full Text] [Related]

  • 4. High sensitive C-reactive protein: a novel biochemical markers and its role in coronary artery disease.
    Mitra B, Panja M.
    J Assoc Physicians India; 2005 Jan 29; 53():25-32. PubMed ID: 15857009
    [Abstract] [Full Text] [Related]

  • 5. High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or useful screening?
    Sellmayer A, Limmert T, Hoffmann U.
    Int Angiol; 2003 Mar 29; 22(1):15-23. PubMed ID: 12771851
    [Abstract] [Full Text] [Related]

  • 6. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
    Sattar N, Murray HM, McConnachie A, Blauw GJ, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Murphy MB, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, Shepherd J, PROSPER Study Group.
    Circulation; 2007 Feb 27; 115(8):981-9. PubMed ID: 17283264
    [Abstract] [Full Text] [Related]

  • 7. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
    Stewart RA.
    Future Cardiol; 2009 May 27; 5(3):231-6. PubMed ID: 19656039
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
    Li JJ, Fang CH.
    Med Hypotheses; 2004 May 27; 62(4):499-506. PubMed ID: 15050096
    [Abstract] [Full Text] [Related]

  • 10. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature.
    Patrick L, Uzick M.
    Altern Med Rev; 2001 Jun 27; 6(3):248-71. PubMed ID: 11410071
    [Abstract] [Full Text] [Related]

  • 11. [Inflammation and C-reactive protein in cardiovascular disease].
    Munk PS, Larsen AI.
    Tidsskr Nor Laegeforen; 2009 Jun 11; 129(12):1221-4. PubMed ID: 19521445
    [Abstract] [Full Text] [Related]

  • 12. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
    Field KM.
    Pharmacotherapy; 2005 Oct 11; 25(10):1365-77. PubMed ID: 16185181
    [Abstract] [Full Text] [Related]

  • 13. [C-reactive protein in cardiovascular risk evaluation].
    Fabijanić D, Banić M, Kardum D.
    Lijec Vjesn; 2006 Oct 11; 128(5-6):167-74. PubMed ID: 16910418
    [Abstract] [Full Text] [Related]

  • 14. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment.
    Libby P, Ridker PM.
    Am J Med; 2004 Mar 22; 116 Suppl 6A():9S-16S. PubMed ID: 15050187
    [Abstract] [Full Text] [Related]

  • 15. Inflammation, C-reactive protein, and atherothrombosis.
    Ridker PM, Silvertown JD.
    J Periodontol; 2008 Aug 22; 79(8 Suppl):1544-51. PubMed ID: 18673009
    [Abstract] [Full Text] [Related]

  • 16. C-reactive protein: a new risk assessment tool for cardiovascular disease.
    Clearfield MB.
    J Am Osteopath Assoc; 2005 Sep 22; 105(9):409-16. PubMed ID: 16239491
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate- and low-cardiovascular-risk individuals for statin therapy.
    Lee KK, Cipriano LE, Owens DK, Go AS, Hlatky MA.
    Circulation; 2010 Oct 12; 122(15):1478-87. PubMed ID: 20876434
    [Abstract] [Full Text] [Related]

  • 18. Inflammatory mechanisms in atherosclerosis: from laboratory evidence to clinical application.
    Blake GJ, Ridker PM.
    Ital Heart J; 2001 Nov 12; 2(11):796-800. PubMed ID: 11770860
    [Abstract] [Full Text] [Related]

  • 19. The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen.
    Wilson AM, Ryan MC, Boyle AJ.
    Int J Cardiol; 2006 Jan 26; 106(3):291-7. PubMed ID: 16337036
    [Abstract] [Full Text] [Related]

  • 20. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander?
    Nordestgaard BG, Zacho J.
    Nutr Metab Cardiovasc Dis; 2009 Oct 26; 19(8):521-4. PubMed ID: 19695857
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.